Skip to main content
SpringerLink
Log in

PD-1 inhibitors cause ILD in NSCLC patients with hypertension

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Chen J, et al. Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors Frontiers in Pharmacology : 20 Sep 2022. Available from: URL: https://doi.org/10.3389/fphar.2022.944342

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

PD-1 inhibitors cause ILD in NSCLC patients with hypertension. Reactions Weekly 1925, 11 (2022). https://doi.org/10.1007/s40278-022-23788-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-23788-4

Search

Navigation